11-dehydro-txb2

Introduction

To understand associated biological information of 11-dehydro-txb2, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with 11-dehydro-txb2?

11-dehydro-txb2 is suspected in Risk factor, cardiovascular, Acute coronary syndrome, thrombocytosis, Chronic ischemic heart disease NOS, Diabetes Mellitus, Diabetes Mellitus, Non-Insulin-Dependent and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with 11-dehydro-txb2

MeSH term MeSH ID Detail
Inflammation D007249 119 associated lipids
Hypercholesterolemia D006937 91 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Brain Ischemia D002545 89 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Atherosclerosis D050197 85 associated lipids
Hyperlipidemias D006949 73 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Asthma D001249 52 associated lipids
Thrombosis D013927 49 associated lipids
Cerebrovascular Disorders D002561 25 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Albuminuria D000419 18 associated lipids
Atrial Fibrillation D001281 16 associated lipids
Cerebral Hemorrhage D002543 13 associated lipids
Polycythemia Vera D011087 13 associated lipids
Death, Sudden, Cardiac D016757 12 associated lipids
Blood Platelet Disorders D001791 12 associated lipids
Renal Artery Obstruction D012078 8 associated lipids
Hypoalphalipoproteinemias D052456 5 associated lipids
Per page 10 20 | Total 20

PubChem Associated disorders and diseases

What pathways are associated with 11-dehydro-txb2

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with 11-dehydro-txb2?

There are no associated biomedical information in the current reference collection.

What functions are associated with 11-dehydro-txb2?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with 11-dehydro-txb2?

There are no associated biomedical information in the current reference collection.

What genes are associated with 11-dehydro-txb2?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with 11-dehydro-txb2?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with 11-dehydro-txb2

Download all related citations
Per page 10 20 50 100 | Total 283
Authors Title Published Journal PubMed Link
Lee CR et al. Cyclooxygenase polymorphisms and risk of cardiovascular events: the Atherosclerosis Risk in Communities (ARIC) study. 2008 Clin. Pharmacol. Ther. pmid:17495879
Helgason CM et al. Platelet aggregation and recruitment with aspirin-clopidogrel therapy. 2008 Cerebrovasc. Dis. pmid:18349532
Signore C et al. Markers of oxidative stress and systemic vasoconstriction in pregnant women drinking > or =48 g of alcohol per day. 2008 Alcohol. Clin. Exp. Res. pmid:18715278
Roethig HJ et al. A 12-month, randomized, controlled study to evaluate exposure and cardiovascular risk factors in adult smokers switching from conventional cigarettes to a second-generation electrically heated cigarette smoking system. 2008 J Clin Pharmacol pmid:18319361
Karon BS et al. Aspirin responsiveness in healthy volunteers measured with multiple assay platforms. 2008 Clin. Chem. pmid:18420732
Bruce EC et al. Platelet thromboxane A2 secretion in patients with major depression responsive to electroconvulsive therapy. 2008 Psychosom Med pmid:18378867
Eikelboom JW et al. Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk. 2008 Circulation pmid:18838564
Dietrich-Muszalska A and Olas B Isoprostenes as indicators of oxidative stress in schizophrenia. 2009 World J. Biol. Psychiatry pmid:19673085
Lowe FJ et al. Evaluation of biomarkers of exposure and potential harm in smokers, former smokers and never-smokers. 2009 Clin. Chem. Lab. Med. pmid:19676143
Stanke-Labesque F et al. Increased urinary leukotriene E4 excretion in obstructive sleep apnea: effects of obesity and hypoxia. 2009 J. Allergy Clin. Immunol. pmid:19596146
Calapai G et al. Cardiovascular biomarkers in groups of established smokers after a decade of smoking. 2009 Basic Clin. Pharmacol. Toxicol. pmid:19175368
Guagnano MT et al. Determinants of platelet activation in hypertensives with microalbuminuria. 2009 Free Radic. Biol. Med. pmid:19280705
Shen H et al. Aspirin Resistance in healthy drug-naive men versus women (from the Heredity and Phenotype Intervention Heart Study). 2009 Am. J. Cardiol. pmid:19660620
Lauring B et al. Laropiprant in combination with extended-release niacin does not alter urine 11-dehydrothromboxane B2, a marker of in vivo platelet function, in healthy, hypercholesterolemic, and diabetic subjects. 2009 J Clin Pharmacol pmid:19833861
Cattaneo M Letter by cattaneo regarding article, "incomplete inhibition of thromboxane biosynthesis by acetylsalicylic Acid: determinants and effect on cardiovascular risk". 2009 Circulation pmid:19546394
Blais N et al. Response to aspirin in healthy individuals. Cross-comparison of light transmission aggregometry, VerifyNow system, platelet count drop, thromboelastography (TEG) and urinary 11-dehydrothromboxane B(2). 2009 Thromb. Haemost. pmid:19652893
Thomson VS et al. Aspirin resistance in Indian patients with coronary artery disease and cardiovascular events. 2009 Oct-Dec J Postgrad Med pmid:20083870
Dragani A et al. The contribution of cyclooxygenase-1 and -2 to persistent thromboxane biosynthesis in aspirin-treated essential thrombocythemia: implications for antiplatelet therapy. 2010 Blood pmid:19887674
Carroll RC et al. Post interventional cardiology urinary thromboxane correlates with PlateletMapping detected aspirin resistance. 2010 Thromb. Res. pmid:19962724
Alusik S et al. The inhibitory effect of statins on urinary 11-dehydrothromboxane levels. 2010 Int Angiol pmid:20502413
Cholette JM et al. Aspirin resistance following pediatric cardiac surgery. 2010 Thromb. Res. pmid:20550971
Montine TJ et al. Elevated ratio of urinary metabolites of thromboxane and prostacyclin is associated with adverse cardiovascular events in ADAPT. 2010 PLoS ONE pmid:20174466
Zisman E et al. Platelet function recovery after cessation of aspirin: preliminary study of volunteers and surgical patients. 2010 Eur J Anaesthesiol pmid:20035230
Boizel R et al. Regulation of oxidative stress and inflammation by glycaemic control: evidence for reversible activation of the 5-lipoxygenase pathway in type 1, but not in type 2 diabetes. 2010 Diabetologia pmid:20535444
Cavalca V et al. Simultaneous quantification of 8-iso-prostaglandin-F(2alpha) and 11-dehydro thromboxane B(2) in human urine by liquid chromatography-tandem mass spectrometry. 2010 Anal. Biochem. pmid:19825360
Dharmasaroja PA and Sae-Lim S Effects of different doses, enteric-coated preparation of aspirin, and sex on urinary 11-dehydrothromboxane B2 in healthy volunteers. 2010 Blood Coagul. Fibrinolysis pmid:20689403
Yassine HN et al. Clinical determinants of aspirin resistance in diabetes. 2010 Diabetes Res. Clin. Pract. pmid:20719400
Warner JH et al. Adaptive regression modeling of biomarkers of potential harm in a population of U.S. adult cigarette smokers and nonsmokers. 2010 BMC Med Res Methodol pmid:20233412
Fukushima H et al. Mechanisms underlying early development of pulmonary vascular obstructive disease in Down syndrome: An imbalance in biosynthesis of thromboxane A2 and prostacyclin. 2010 Am. J. Med. Genet. A pmid:20583254
Ferrante E et al. Determinants of thromboxane biosynthesis in rheumatoid arthritis: Role of RAGE and oxidant stress. 2010 Free Radic. Biol. Med. pmid:20541603
Antonino MJ et al. Antiplatelet effects of aspirin with phytosterols: comparison with non-enteric coated aspirin alone. 2010 Thromb. Res. pmid:19446864
Santilli F et al. Postprandial hyperglycemia is a determinant of platelet activation in early type 2 diabetes mellitus. 2010 J. Thromb. Haemost. pmid:20088941
Addad F et al. Response variability to aspirin and one-year prediction of vascular events in patients with stable coronary artery disease. 2010 J. Thromb. Thrombolysis pmid:19381450
Frost-Pineda K et al. Biomarkers of potential harm among adult smokers and nonsmokers in the total exposure study. 2011 Nicotine Tob. Res. pmid:21330277
Varma D et al. Comparison of UHPLC and HPLC methods for the assay of prostanoids: "are the methods equivalent in terms of accuracy and precision?". 2011 Bioanalysis pmid:21510759
Spectre G et al. Twice daily dosing of aspirin improves platelet inhibition in whole blood in patients with type 2 diabetes mellitus and micro- or macrovascular complications. 2011 Thromb. Haemost. pmid:21800009
Hoh CM et al. Evaluation of effects of low-dose aspirin administration on urinary thromboxane metabolites in healthy dogs. 2011 Am. J. Vet. Res. pmid:21801060
Gao F et al. Effect of polymorphism and type II diabetes on aspirin resistance in patients with unstable coronary artery disease. 2011 Chin. Med. J. pmid:21740787
Shen L et al. In vivo oxidation, platelet activation and simultaneous occurrence of natural immunity in atherosclerosis-prone mice. 2011 Isr. Med. Assoc. J. pmid:21845968
Hall JA et al. Dietary fish oil alters the lysophospholipid metabolomic profile and decreases urinary 11-dehydro thromboxane Bâ‚‚ concentration in healthy Beagles. 2011 Vet. Immunol. Immunopathol. pmid:21925741
Lessiani G et al. Inflammation, oxidative stress and platelet activation in aspirin-treated critical limb ischaemia: beneficial effects of iloprost. 2011 Thromb. Haemost. pmid:21103664
Lynch CM et al. The role of thromboxane A(2) in the pathogenesis of intrauterine growth restriction associated with maternal smoking in pregnancy. 2011 Prostaglandins Other Lipid Mediat. pmid:21723954
Di Minno MN et al. Genotype-independent in vivo oxidative stress following a methionine loading test: maximal platelet activation in subjects with early-onset thrombosis. 2011 Thromb. Res. pmid:21669453
Halawani SH et al. Aspirin failure in patients presenting with acute cerebrovascular ischaemia. 2011 Thromb. Haemost. pmid:21544317
Gonçalves LH et al. Urinary 11-dehydro thromboxane B₂ levels in type 2 diabetic patients before and during aspirin intake. 2011 Clin. Chim. Acta pmid:21510926
Simeoni S et al. Stress-induced salivary cortisol secretion during hypobaric hypoxia challenge and in vivo urinary thromboxane production in healthy male subjects. 2011 Stress pmid:21434833
Gremmel T et al. Comparison of methods to evaluate aspirin-mediated platelet inhibition after percutaneous intervention with stent implantation. 2011 Platelets pmid:21231857
Thomason J et al. Platelet cyclooxygenase expression in normal dogs. 2011 Sep-Oct J. Vet. Intern. Med. pmid:21985141
Li C et al. Reversal of the anti-platelet effects of aspirin and clopidogrel. 2012 J. Thromb. Haemost. pmid:22268852
Lemkes BA et al. The influence of aspirin dose and glycemic control on platelet inhibition in patients with type 2 diabetes mellitus. 2012 J. Thromb. Haemost. pmid:22252020